Monday, March 24, 2025 : TechInvention Lifecare Pvt. Ltd. (TechInvention) is proud to announce a strategic collaboration with Belgium-based Quantoom Biosciences (Quantoom). The Memorandum of Understanding (MoU) was formally signed during the Belgian Economic Mission to India on Tuesday, March 4, 2025, in the presence ofHer Royal Highness Princess Astrid of Belgium, industry leaders and key stakeholders from both nations.
As part of this
collaboration, TechInvention is introducing Quantoom’s cutting-edge RNA
manufacturing solutions—to Indiawith a strong focus on accessibility,
scalability, and affordability. This advanced suite of technologies is designed
to de-risk and accelerate the development of RNA-based vaccines. Complementing
this, TechInvention will leverage its translational researchexpertise,
regulatory know-how, and GMP manufacturing capabilities to streamline developing,
scaling, and commercialising novel RNA-based products. This partnership
represents a transformative milestone in India’s biotechnology landscape,
establishing end-to-end mRNA production capabilities at TechInvention’s
forthcoming EU-GMP-approved facility, the Global Collaborative Centre for
Medical Countermeasures (GCMC), in Mumbai.
With a One
Health approach, this collaboration extends beyond human health to encompass
animal and environmental health. The technology is designed for environmental
sustainability, integrating modular, low-carbon-footprint mRNA systems that
support global decarbonization efforts. It aligns with worldwide initiatives to
enable access to next-generation RNA technologies, ensuring that low- and
middle-income countries (LMICs) benefit from locally manufactured, cost-effective,
and scalable solutions.
José Castillo, CEO, Quantoom Biosciences, added:
"At Quantoom, our mission is to enable our partners to accelerate their
m(sa)RNA-based vaccines development, thanks to our end-to-end N-Force Toolbox.We
think that our technology will, by design,make RNA products accessible and
scalable globally. Partnering with TechInvention in India is a vital step
toward achieving this goal, into the most populated country in the world, and
we look forward to enabling groundbreaking developments in the field of
RNA-based medicines."
Syed Ahmed, Director & CEO,
TechInvention, commented:
"We are excited to bring Quantoom’s cutting-edge mRNA technology to
India, revolutionizing RNA drugs development and manufacturing. This
partnership is a significant step toward strengthening India’s preparedness for
future pandemics while ensuring broader access to RNA-based innovations across
LMICs."
This collaboration positions India as a hub
for next-gen RNA-based vaccines, driving global partnerships for equitable
healthcare.
MoU Signed Between Techinvention and
Quantoom Biosciences, in the presence of Her Royal Highness Princess Astrid of
Belgium during the Belgian Economic Mission to India
For further information, please contact:
TechInvention Lifecare Pvt. Ltd. – connect@techinvention.biz
Quantoom Biosciences – Jonathan Lecocq, j.lecocq@quantoom.com